Analyzing the clinical-pathological characteristics of HER-2 ultra-low breast cancer in a medium-sized Brazilian city: a brief communication
DOI:
https://doi.org/10.34019/1982-8047.2023.v49.42185Palavras-chave:
Neoplasias da Mama, Genes erbB-2, Antígeno Ki-67, Receptores de EstrogênioResumo
N/A
Downloads
Referências
Instituto Nacional de Câncer (BR). Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [acesso em 2023 jul 12]. Disponível em: https:// www.inca.gov.br/sites/ufu.sti.inca.local/files//media/ document//estimativa-2023.pdf
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. DOI: 10.3322/caac.21660
Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. DOI: 10.1093/annonc/mdt303
Shi J, Zhang L, Geng C et al. Her-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study. Frontiers in Oncology. 2023; 13:1-9. DOI: 10.3389/fonc.2023.1210314
Giordano SH, Franzoi MAB, Temin S et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022; 40(23):2612-35. DOI: 10.1200/jco.22.00519
Venetis K, Crimini E, Sajjadi E et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022; 9:834651. DOI:10.3389/fmolb.2022.834651
Tuluhong D, Li X, Gao H et al. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy. Eur J Cancer Prev. 2023; 32(4):377-87. DOI: 10.1097/CEJ.0000000000000813
Chen Z, Jia H, Zhang H, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Research and Treatment. 2023; 202(2):313-23. DOI: 10.1007/s10549-023-07079-8
Allison K, Hammond M, Dowsett M et.al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020; 38(12):1346-66. DOI: 10.1200/jco.19.02309
Finkelman B, Zhang H, Hicks D et al. The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15(3):808. DOI: 10.3390/cancers15030808
Lakhani SR, Ellis IO, Schnitt SJ et al. World Health Organization classification of tumours of the breast. 4th. ed. Lyon: IARC Press; 2012.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Tony Maronesi Bagio, Paulo Gil Katsuda, Deolino João Camilo Júnior, José Cândido Caldeira Xavier Júnior
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
